DrugTimes001管理团队
-
祝贺恒瑞、康方、劲方、启函！更多消息，关于CAR-NK细胞疗法、干细胞试管婴儿疗法、EpCAM ADC报告一例患者死亡、Generation Bio裁员90%
关注药时代，及时获得有价值的新药研发资讯！
-
【SELL】A Highly Potent, Selective, Tissue-Enriched Oral Pan-KRAS (ON & OFF) Inhibitor for licensing
If interested, please contact DrugTimes BD Team asap! Our email address is: BD@drugtimes.cn
-
Everest Medicines has strategically increased its stake in I-Mab, becoming its largest shareholder
DrugTimes team will continue to follow and report. Please stay tuned. Many thanks!
-
Merck & Co. is laying off 6,000 employees, and the reason is…
DrugTimes team will continue to follow and report. Please stay tuned. Many thanks!
-
Trump called out 17 pharmaceutical companies to lower drug prices and subsidize the United States!
DrugTimes team will continue to follow and report. Please stay tuned. Many thanks!
-
I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares
For more DrugTimes bio-news, please follow DrugTimes. Many thanks!
-
I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health
For more bio-news, please follow DrugTimes. Many thanks!
-
AbbVie boasts that it will become the largest CNS company in the industry next year!
In the field of biopharmaceuticals, there is no eternal No. 1, only infinite possibilities
-
An asset similar to Roche’s trontinemab | DrugTimes BD Project
If interested in this asset, please feel free to contact the BD team at DrugTimes immediately! Please send an email to BD@drugtimes.cn
-
CNS赛道火热升温！罗氏trontinemab数据积极！感兴趣类似产品？请速速联系 | 药时代BD项目DTC-082
如果贵公司对该项目感兴趣，欢迎立即联系药时代BD团队！请发送邮件到BD@drugtimes.cn
